Peptides for Gravel Cyclists: A Phase-by-Phase Look at Unbound, SBT GRVL, and Mid South
How peptide therapy can support the body through the mitochondrial demand, saddle injury, and nerve compression of long gravel events. Organized the way gravel riders actually train: base, build, race, recovery, off-season.
In this article
Key Takeaways
- Gravel-specific wear has four parts that scale with event length: mitochondrial demand at the top of the curve for 14-hour days, sit-bone tissue damage from 6+ hours of seated pressure, handlebar palsy and hot foot from compression neuropathy, and saddle-to-cleat kinetic chain wear that often surfaces two weeks after the race.
- Peptide therapy in gravel is organized around training phases rather than continuous dosing: MOTS-c builds during base, BPC-157 ramps during build, both taper in race week, and NAD+ + BPC-157 drive the post-event recovery window.
- MOTS-c is one of the few peptides in clinical use that targets mitochondria directly. It was discovered at USC in 2015 as the first peptide encoded by mitochondrial DNA. The feel difference shows up on long zone 2 efforts, not short anaerobic ones.
- CJC-1295/Ipamorelin is an off-season peptide for masters riders, supporting overnight tissue recovery and lean mass retention through winter. It pauses 7-10 days before any A-race to avoid water retention.
Mile 142 Out of Emporia
The scene
You crossed the second flooded creek about an hour ago. Your shoes are still wet. The chunky limestone climbs through the Flint Hills have ground your sit bones into hamburger somewhere around mile 90, and your right hand has gone numb from the ring finger out for the last 35 miles. The next aid station is 18 miles of false flat into a headwind.
This is what Unbound Gravel feels like at hour ten. SBT GRVL has a similar shape at altitude. Mid South puts the same load into mud and Oklahoma red clay. The Rift in Iceland adds black sand. The events are all different. The body math is the same: 12 to 15 hours in the saddle, single-day, with mitochondrial demand that nothing in normal training prepares you for.
Gravel Riders Think in Phases
Most peptide content treats the molecules as continuous dosing: take this peptide daily, here is what it does. That framing does not match how cyclists actually train. Periodization is the organizing principle of every modern coaching program, and peptide therapy fits inside it the same way that intervals, zone 2 volume, and sleep do. The right peptide at the wrong phase is wasted dosing.
This guide is organized the way the season actually moves: base build, build block, race week, race day, post-event recovery, off-season. The same four molecules show up across phases (MOTS-c, BPC-157, NAD+, CJC-1295/Ipamorelin), but the role each one plays shifts as the demand on the body shifts.
Base Build (8-12 Weeks Out)
The base block is when aerobic capacity and mitochondrial density actually grow. Long zone 2 rides, controlled volume, no real intensity. The goal is to expand the engine that will get you through 14 hours on race day. This is also the phase where many riders bring MOTS-c into the protocol.
MOTS-c was discovered at USC in 2015 and is the first peptide ever found to be encoded by mitochondrial DNA rather than nuclear DNA. In animal models it improves insulin sensitivity, increases fat oxidation, and acts as an exercise mimetic at the mitochondrial level. The mechanism takes 3-6 weeks to start showing up subjectively on long rides, which is why starting it at the top of the base block means you will feel it by mid-build.
NAD+ at a maintenance dose makes sense here too. Heavy base volume depletes the NAD+ pool faster than easy training does, and the maintenance dose keeps cellular energy steady through the increasing load. For masters riders (40+), the base block is also when CJC-1295/Ipamorelin enters the picture. The deep-sleep GH pulse it supports is exactly when overnight tissue recovery happens, which is exactly what you need on top of high base volume.
BPC-157 at this phase is conditional. If you are carrying anything chronic (lingering knee tracking, a sit-bone bruise that has not fully resolved, an old patellar tendinopathy), this is the moment to address it. Six to eight weeks of consistent BPC-157 dosing during base will get most chronic stuff to a manageable place before build volume starts compounding it.
Build Block (4-8 Weeks Out)
The build block is where race-specific demand goes in. Five to seven hour zone 2 rides on real gravel, some threshold work, simulating the long-day pattern of the actual race. Weekly volume is at its peak. This is when you find out if your saddle, your bike fit, and your nutrition strategy will hold up. If they will not, you find out now and not on race day.
MOTS-c is now showing up where it should: on rides over three hours, fatigue comes later in the back half. The mitochondrial work is mostly done by this point, and the dose stays constant. BPC-157 becomes more central. The bigger weekly volume creates more wear on sit bones, hands, and knees, and daily BPC-157 during this block is one way to keep the cumulative load from outpacing recovery.
NAD+ usually gets bumped to a higher dose 48 hours after the biggest weekly ride. That window is when most of the cellular repair from the long day actually runs, and the elevated dose supports it. CJC-1295/Ipamorelin continues at the base-block dose for masters riders. If you are not a masters rider, you can skip CJC/Ipa entirely; the build block does not require it.
Race Week
Race week is taper. Volume drops sharply, intensity stays sharp but brief, and the focus is sleep, hydration, and arriving at the start line rested. The peptide protocol shifts to match.
MOTS-c tapers to a maintenance dose. The mitochondrial work is done. Race day is about expressing what you built, not building more. BPC-157 moves to held-in-reserve mode. If a tendon or sit-bone flares during race week, you have a tool. If everything is fine, the prevailing wisdom is to skip dosing rather than introduce variables.
CJC-1295/Ipamorelin pauses 7-10 days out. The water retention from GH-axis peptides is small but real, and the goal race morning is to be light, not pumped. NAD+ continues at its build-block maintenance dose; it does not need to taper.
Race Day
Race day is execution. The peptide protocol is not what is getting you to the finish line. Training is. The protocol exists to make sure you arrive at the start line healthy and recover well enough to do this again.
Two practical notes. First: do not dose anything new race morning. Whatever your pre-race ritual is, that is the ritual. Second: BPC-157 is not a painkiller. Do not dose it expecting to mask discomfort so you can push through. It does not work that way, and it is not what it is for.
If you race UCI events or USAC-sanctioned categories where WADA rules apply, check the prohibited list directly for whatever is in your stack. Some peptides are prohibited in-competition only, others year-round. The big gravel events (Unbound, SBT GRVL, Mid South, BWR) are non-sanctioned and do not test.
Post-Event Recovery (7-14 Days)
A 200-mile gravel race produces real tissue damage. Sit-bone bruising, hand neuropathy that lingers for days, knee tracking that flares, the deep aerobic fatigue that takes two full weeks to clear. The post-event window is where peptide therapy does some of its highest-leverage work.
NAD+ at the higher dose 24-48 hours post is the cellular-energy repair window. This is when mitochondrial damage gets repaired, oxidative stress gets cleared, and the systemic recovery actually runs. A common pattern is to run the elevated dose for the first 5-7 days post-event, then return to maintenance.
BPC-157 daily for 7-10 days handles the tissue side. Sit bones, hands, knees, whatever got beat up. MOTS-c stays off during the first 7 days. The cellular machinery is busy with repair, not adaptation, and dosing during that window is wasted. Sleep, hydration, easy spinning, then start adding the longer rides back at week two.
Off-Season Build
The off-season is when many masters athletes lose ground if they are not deliberate. Volume drops, weight drifts up, sleep gets better but lean mass softens. CJC-1295/Ipamorelin is the off-season peptide for this exact pattern: it supports lean tissue retention through the lower-volume months and protects the deep-sleep GH pulse that does most of the overnight repair.
BPC-157 cycled (4 weeks on, 2 off) is useful for addressing any chronic stuff that you compensated through during race season. The Achilles you taped, the patellar tendon you babied, the hip flexor that flared every long ride. The off-season is the window to actually resolve them.
NAD+ at maintenance continues year-round. MOTS-c off-season is a personal call: some riders cycle it through the winter base, some hold it until the next pre-build to refresh receptor sensitivity. Both work.
A Few Practical Questions
Related Guides
Continue reading about peptides and protocols that pair well with this guide.
Pinealon, PE-22-28 & Selank Guide (2026)
Three peptides, three layers of brain support. Pinealon restores sleep architecture through pineal gland regulation. PE-22-28 drives neurogenesis by blocking the TREK-1 potassium channel. Selank calms anxiety through GABA modulation without sedation or dependence. Together they rebuild, grow, and protect neural tissue from three independent angles.
Is CJC-1295/Ipamorelin FDA Approved? (2026 Answer)
The short answer is no. CJC-1295 and Ipamorelin are not FDA-approved drugs. They are compounded medications, prescribed by licensed providers and prepared by regulated pharmacies. Here is what that actually means for you, how it compares to FDA-approved peptides, and why the distinction matters less than most people think.
Is Sermorelin FDA Approved? Yes Until 2008 (Then What?)
Sermorelin has a unique regulatory history. It was FDA-approved in 1997 as Geref Diagnostic for testing pituitary function, and its therapeutic form (Geref) was used for pediatric growth hormone deficiency. Then the manufacturer discontinued it in 2008. Today Sermorelin is only available as a compounded medication. Here is the full story.
Learn more about peptide therapy
Peptide therapy in the US is prescription-only and requires evaluation by a licensed provider. Browse the individual peptides to read about what each one does.